PEG-Modified Binding Complexes for Soluble Nonspecific Reaction Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunological measurement technologies face challenges with non-specific reactions, particularly when high sample concentrations are used, leading to increased non-specific reaction substances, necessitating large amounts of expensive biological materials like antibodies, which are costly and vary in effectiveness due to lot-to-lot differences, and existing solutions do not adequately address solubility and inhibitory effects.
Innovation Solution
A non-specific reaction inhibitor comprising a complex of a peptide or nucleic acid molecule that specifically binds to non-specific reaction substances, modified with a polymer such as PEG, ensuring high solubility, cost-effectiveness, and minimal lot-to-lot variation, allowing sufficient addition even at high sample concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-generated harmful factors
If IgG or IgM is used as an antibody against non-specific reactive substances, then non-specific reactions are inhibited, but immune complexes are formed resulting in immunonephelometric reaction and accurate measurement values cannot be obtained
Solution Approach 1:
The patent segments the IgG antibody into smaller Fab' fragments through enzymatic digestion. This segmentation reduces the molecular size from approximately 150 kDa to 55 kDa, preventing immune complex formation while retaining the ability to bind non-specific reactive substances. The segmented Fab' fragments can still effectively inhibit non-specific reactions without causing the immunonephelometric interference that whole IgG molecules cause.
Solution Approach 2:
The patent extracts and removes the Fc region of the IgG antibody, keeping only the Fab' antigen-binding fragments. This extraction eliminates the portion of the antibody that causes immune complex formation and immunonephelometric reactions, while preserving the functional region that binds to non-specific reactive substances. The removed Fc region is the source of the harmful immunonephelometric effect.
2Measurement precision
If Fab' fragments are used to reduce hydrophobicity and prevent immunonephelometric reaction, then measurement accuracy is maintained, but the non-specific inhibitory effect is weakened due to decomposition and insufficient molecular size
Solution Approach 1:
The patent merges multiple Fab' fragments with a polyethylene glycol (PEG) polymer backbone to create a conjugate structure. This combination maintains the small molecular size advantage of Fab' fragments while the PEG polymer provides enhanced solubility and stability. The merged structure prevents decomposition and maintains persistent non-specific inhibitory activity throughout the measurement process.
Solution Approach 2:
The patent creates a composite material consisting of protein (Fab' fragment) and polymer (PEG) components. This composite structure combines the specific binding capability of the Fab' fragment with the solubility-enhancing and stability-providing properties of the PEG polymer. The composite nature ensures both measurement accuracy and sustained non-specific reaction inhibition.
3Measurement precision
If the amount of sample is increased to increase sensitivity of reagents, then sensitivity is improved, but the amount of non-specific reaction substances increases significantly requiring large amounts of expensive biological materials
Solution Approach 1:
The patent replaces expensive, biologically-derived antibodies and antibody fragments with a synthetic or semi-synthetic PEG-Fab' conjugate that is more cost-effective. This substitute material can be used in larger quantities without significant cost increase, enabling effective inhibition even when large amounts are required due to increased sample volumes. The cost-effectiveness allows disposable use in high-concentration scenarios.
Solution Approach 2:
The patent changes the molecular weight parameter of the inhibitory substance by conjugating multiple Fab' fragments (each ~55 kDa) with a PEG polymer to create a larger molecular weight conjugate. This parameter change increases the inhibitory capacity per molecule, allowing effective non-specific reaction inhibition with smaller total amounts of inhibitor material, even when sample volumes are increased for sensitivity.
4Object-generated harmful factors
If the molecular size is enlarged by modifying antibody fragments with polymer compounds, then non-specific inhibitory effect is enhanced, but solubility improvement is insufficient and sufficient addition amount cannot be ensured when sample amount is increased
Solution Approach 1:
The patent uses polyethylene glycol (PEG) as an intermediary substance that mediates between the hydrophobic Fab' fragment and the aqueous solution environment. The PEG polymer acts as a solubility-enhancing intermediary, providing hydrophilic character to the otherwise hydrophobic protein fragment. This intermediary function ensures high solubility and enables sufficient addition amounts even when large volumes are required.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides effective non-specific reaction inhibition at lower costs, with reduced lot-to-lot variation, ensuring high solubility and sufficient addition amounts, thus enhancing the accuracy of immunological measurements even with high sample concentrations.
Implementation Method 1
a peptide or nucleic acid molecule that specifically binds to a non-specific reaction substance
Implementation Method 2
modifying a peptide that is even smaller in molecular weight than Fab′ and has the ability to bind to non-specific reaction substances with a polymer such as polyethylene glycol (PEG)
Data Source
AI summary
Provided is a non-specific reaction inhibitor that has high solubility, can be added in sufficient amounts, is inexpensive, and has small variation among different lots. The non-specific reaction inhibitor of the present invention comprises a complex of a peptide or nucleic acid molecule that specifically binds to a non-specific reaction substance and a polymer compound.